Glycomic Therapeutics Market is Projected to Reach US$551,756 Million by 2032, at a CAGR of 16.1% from 2023 to 2032 | Persistence Market Research [Yahoo! Finance]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Yahoo! Finance
Discover key players, technology trends, market drivers, challenges, and opportunities, along with insights into collaborations and the future outlook. New York, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Market Overview: The Glycomic Therapeutics Market is a burgeoning sector within the pharmaceutical and biotechnology industry, focused on the development of therapeutics that target glycomics, the study of complex carbohydrates known as glycans. Glycans play a crucial role in various cellular processes, including cell signaling, immune responses, and disease development. The market for glycomic therapeutics has gained prominence due to its potential to address a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and rare genetic conditions. The Glycomic Therapeutics Market has witnessed significant growth in recent years, driven by the increasing understanding of glycan-related diseases and the emergence of innovative technologies. The global glycomic t
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics, Inc. (NYSE: PLX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 [Yahoo! Finance]Yahoo! Finance
PLX
Earnings
- 11/6/23 - Beat
PLX
Sec Filings
- 4/29/24 - Form DEF
- 4/3/24 - Form 4
- 3/14/24 - Form 10-K
- PLX's page on the SEC website